LEO Science & Tech Hub (The Hub), a research and development unit of LEO Pharma, has initiated 2 collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital.
The Hub, which identifies, develops, and funds innovative solutions that improve the lives of patients with skin diseases, will provide research funding to support development of novel imaging technology using a disposable microbiopsy device. Conor L Evans, PhD, assistant professor, Harvard Medical School, will lead the project. The Evans Lab’s specializes in microscopy and spectroscopy for understanding cancer and dermatology disorders. The research project collaboration will explore novel imagine technologies that will to enable non-invasive, high-resolution, real-time pharmacokinetic/pharmacodynamic measurements with help of the lab’s coherent Raman scattering (CRS) technology (Figure 1).
Figure 1. Coherent Raman imaging may one day allow real-time biological measurements to benefit patients. Here’s an image of mouse skin “tuned” into the vibrational frequencies of lipids taken at the surface of skin and shows hairs and the hexagonally packed corneocytes.
The second project includes work with Walfre Franco, PhD, clinical instructor, and Adam Raff, MD, PhD, clinical associate from R Rox Anderson’s Lab. The Anderson Lab will focus on discovering new optical treatments and diagnostics for dermatologic applications, and will seek to develop a suture-free and disposable microbiopsy device that may allow for a non-scarring sampling procedure of full-thickness skin microbiopsies.
"We are excited to enter these collaborations with the Wellman Center for Photomedicine at Mass General Hospital and are honored to work with scientists at the forefront of imaging technology and microbiopsy research,” said Michael Sierra, PhD, VP, The Hub. “At LEO Science & Tech Hub, we firmly believe in the power of collective effort and are always seeking cutting-edge technologies to advance non-invasive biopsy and imaging technologies for patients with skin diseases.”
—Julie Gould (Mazurkiewicz)
LEO Science & Tech Hub (The Hub), a research and development unit of LEO Pharma, has initiated 2 collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital.
The Hub, which identifies, develops, and funds innovative solutions that improve the lives of patients with skin diseases, will provide research funding to support development of novel imaging technology using a disposable microbiopsy device. Conor L Evans, PhD, assistant professor, Harvard Medical School, will lead the project. The Evans Lab’s specializes in microscopy and spectroscopy for understanding cancer and dermatology disorders. The research project collaboration will explore novel imagine technologies that will to enable non-invasive, high-resolution, real-time pharmacokinetic/pharmacodynamic measurements with help of the lab’s coherent Raman scattering (CRS) technology (Figure 1).
Figure 1. Coherent Raman imaging may one day allow real-time biological measurements to benefit patients. Here’s an image of mouse skin “tuned” into the vibrational frequencies of lipids taken at the surface of skin and shows hairs and the hexagonally packed corneocytes.
The second project includes work with Walfre Franco, PhD, clinical instructor, and Adam Raff, MD, PhD, clinical associate from R Rox Anderson’s Lab. The Anderson Lab will focus on discovering new optical treatments and diagnostics for dermatologic applications, and will seek to develop a suture-free and disposable microbiopsy device that may allow for a non-scarring sampling procedure of full-thickness skin microbiopsies.
"We are excited to enter these collaborations with the Wellman Center for Photomedicine at Mass General Hospital and are honored to work with scientists at the forefront of imaging technology and microbiopsy research,” said Michael Sierra, PhD, VP, The Hub. “At LEO Science & Tech Hub, we firmly believe in the power of collective effort and are always seeking cutting-edge technologies to advance non-invasive biopsy and imaging technologies for patients with skin diseases.”
—Julie Gould (Mazurkiewicz)
LEO Science & Tech Hub (The Hub), a research and development unit of LEO Pharma, has initiated 2 collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital.
The Hub, which identifies, develops, and funds innovative solutions that improve the lives of patients with skin diseases, will provide research funding to support development of novel imaging technology using a disposable microbiopsy device. Conor L Evans, PhD, assistant professor, Harvard Medical School, will lead the project. The Evans Lab’s specializes in microscopy and spectroscopy for understanding cancer and dermatology disorders. The research project collaboration will explore novel imagine technologies that will to enable non-invasive, high-resolution, real-time pharmacokinetic/pharmacodynamic measurements with help of the lab’s coherent Raman scattering (CRS) technology (Figure 1).
Figure 1. Coherent Raman imaging may one day allow real-time biological measurements to benefit patients. Here’s an image of mouse skin “tuned” into the vibrational frequencies of lipids taken at the surface of skin and shows hairs and the hexagonally packed corneocytes.
The second project includes work with Walfre Franco, PhD, clinical instructor, and Adam Raff, MD, PhD, clinical associate from R Rox Anderson’s Lab. The Anderson Lab will focus on discovering new optical treatments and diagnostics for dermatologic applications, and will seek to develop a suture-free and disposable microbiopsy device that may allow for a non-scarring sampling procedure of full-thickness skin microbiopsies.
"We are excited to enter these collaborations with the Wellman Center for Photomedicine at Mass General Hospital and are honored to work with scientists at the forefront of imaging technology and microbiopsy research,” said Michael Sierra, PhD, VP, The Hub. “At LEO Science & Tech Hub, we firmly believe in the power of collective effort and are always seeking cutting-edge technologies to advance non-invasive biopsy and imaging technologies for patients with skin diseases.”
Read about the latest insights in skin cancer care with a new whitepaper on advanced basal cell carcinoma and advanced cutaneous squamous cell carcinoma. View the complimentary resource today!
The US Food and Drug Administration recently announced approval of an injectable poly-L-lactic acid, for the correction of fine lines and wrinkles in cheek areas.
The US Food and Drug Administration recently announced approval of an injectable poly-L-lactic acid, for the correction of fine lines and wrinkles in cheek areas.
In this interview with The Dermatologist, Dr Abigail Waldman discusses her session, "Managing Melanoma Risk and Prognosis by Gene Expression Profiling and Nodal Staging," at the 2023 ACMS Annual Meeting.
In this interview with The Dermatologist, Dr Abigail Waldman discusses her session, "Managing Melanoma Risk and Prognosis by Gene Expression Profiling and Nodal Staging," at the 2023 ACMS Annual Meeting.
In this interview, Dr Peter Young discusses how the Keeps platform utilizes digital solutions to provide accessible and evidence-based care for male androgenetic alopecia.
In this interview, Dr Peter Young discusses how the Keeps platform utilizes digital solutions to provide accessible and evidence-based care for male androgenetic alopecia.
Explore how patients and providers can align on defining atopic dermatitis (AD) flares to improve communication, treatment decisions, and shared decision-making. Take this interactive quiz to test your knowledge and learn how patient-centered...
Explore how patients and providers can align on defining atopic dermatitis (AD) flares to improve communication, treatment decisions, and shared decision-making. Take this interactive quiz to test your knowledge and learn how patient-centered...
How well do you understand the patient perspective on atopic dermatitis flares? Take this quiz to explore key patient-described flare indicators, emotional and social impacts, and insights from NEA research.
How well do you understand the patient perspective on atopic dermatitis flares? Take this quiz to explore key patient-described flare indicators, emotional and social impacts, and insights from NEA research.
Test your knowledge of how patients with atopic dermatitis (AD) define and experience flares. This quiz highlights key indicators, patient-described attributes, and insights from the NEA’s research into AD flare triggers and symptoms.
Test your knowledge of how patients with atopic dermatitis (AD) define and experience flares. This quiz highlights key indicators, patient-described attributes, and insights from the NEA’s research into AD flare triggers and symptoms.
1. How do JAK inhibitors differ from traditional immunosuppressant treatments for atopic dermatitis?a) They work extracellularly, directly blocking cytokines.b) They target inflammation at the intracellular level and are more selective.c)...
1. How do JAK inhibitors differ from traditional immunosuppressant treatments for atopic dermatitis?a) They work extracellularly, directly blocking cytokines.b) They target inflammation at the intracellular level and are more selective.c)...
